SJEPD031786_D2.RNA-Seq
EPN · Anaplastic EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Anaplastic EPN
- cancer_type
- EPN
- subtype
- Anaplastic EPN
- age_years
- 1.08
- e1_e2
- E2
- umap1_2d
- -5.489621592
- umap2_2d
- 2.701838888
- umap1_3d
- -1.219752292
- umap2_3d
- 3.919143062
- umap3_3d
- -1.424971053
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- E2F_TARGETS+0.390
- G2M_CHECKPOINT+0.380
- MYC_TARGETS_V1+0.380
- PANCREAS_BETA_CELLS+0.290
- SPERMATOGENESIS+0.290
- ANDROGEN_RESPONSE+0.210
- MTORC1_SIGNALING+0.160
- UV_RESPONSE_DN+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.050
Top 10 suppressed
- MYOGENESIS-0.430
- APICAL_JUNCTION-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- WNT_BETA_CATENIN_SIGNALING-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
- ADIPOGENESIS-0.320
- UV_RESPONSE_UP-0.320
- APICAL_SURFACE-0.290
- P53_PATHWAY-0.290
- HEDGEHOG_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.923 |
| 2 | SRR3147744 | — | — | 0.867 |
| 3 | TCGA-AO-A1KS-01A-11R-A13Q-07 | — | B | 0.837 |
| 4 | ERR2598094 | fetal | fetal | 0.828 |
| 5 | C3N-01016 | — | cohortA3 | 0.823 |
| 6 | BS_ZV68CES9 | medulloblastoma | — | 0.823 |
| 7 | MNG640 | — | — | 0.822 |
| 8 | 242a1034-4aae-46f8-a40d-91710af30d0a | — | — | 0.818 |
| 9 | R158 | — | — | 0.815 |
| 10 | R157 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |